The Harvard Medical School Family Health Guide
Blood Disorders
Harvard Health Publications
Order the Book
Contact Us
Sign up for our free e-mail newsletter, HEALTHbeat.  
Email Address:
First Name (optional):
Special Health Information Reports
Weight Loss
Prostate Disease
Vitamins and Minerals
Aching Hands
See All Titles
Browse Health Information
Common Medical Conditions
Wellness & Prevention
Emotional Well Being & Mental Health
Women’s Health
Men’s Health
Heart & Circulatory Health
About the Book
New Information
About the Team
Order the Book
Return to the Family Health Guide Home Page
  Harvard Health Publications
contact us


Return to Chapter Index

Anemia sufferers now have expanding options for treatment

Anemia, the lack of oxygen-carrying red blood cells, can cause severe fatigue. Luckily, more of the people suffering from the disorder, namely those undergoing chemotherapy and recovering from bone marrow transplants, are finding help in recombinant erythropoietin therapy. This treatment involves injections or IVs of genetically engineered proteins to stimulate the body’s natural production of red blood cells, thus curing anemia.

Erythropoietin therapy for chemo patients

People who undergo chemotherapy to destroy fast-growing cancer cells often suffer from anemia because the treatment also destroys the cells that give rise to red blood cells. In July 2002, the Food and Drug Administration approved the use of an erythropoietic protein for the treatment of anemia related to chemotherapy.

This protein, Aranesp (darbepoetin alfa), works by promoting the formation of new red blood cells. Already in use to treat patients with anemia related to kidney failure, Aranesp is similar to EPOGEN and Procrit, two drugs currently used to treat anemia in chemotherapy patients. But Aranesp lasts roughly three times longer in the body. While patients may need an injection of EPOGEN or Procrit three times a week, Aranesp is needed just once weekly or every other week. This means fewer visits to the doctor for treatments by chemotherapy patients. Using Aranesp is also less expensive than EPOGEN and Procrit, although most insurers are likely to cover the cost.

Erythropoietin therapy for bone marrow transplants

Erythropoietin therapy is also beginning to show promise for the treatment of anemia in patients who receive donated bone marrow transplants. Bone marrow tissue produces new blood cells, and people receive a transplant of this tissue when their own bone marrow is unable to produce healthy blood cells. Transplant patients often require repeated blood transfusions to maintain healthy levels of hemoglobin, the oxygen-carrying protein in red blood cells. In previous studies, researchers have had limited success using very high, costly doses of erythropoietin therapy to stimulate red blood cell production in these patients. Now a study published in the June 2002 issue of Experimental Hematology shows low doses of erythropoietin therapy are quite successful at boosting and maintaining hemoglobin levels if timed correctly.

Researchers investigated the optimal timing and dosage for erythropoietin therapy in 34 patients who had received a bone marrow transplant. In the first trial, patients began receiving a high dose of erythropoietin daily immediately following the transplant. In the second trial, patients received a lower dose of the treatment three times per week beginning sometime between 2 months and four years following the transplant. Patients in the third trial began receiving a low dose of erythropoietin twice a week 35 days after transplant. If hemoglobin levels were considered insufficient (below 8 g/dL), patients received transfusions. To determine how well the erythropoietin worked, researchers measured the hemoglobin levels of the patients and recorded the number of transfusions required.

The researchers found patients in the first trial benefited little from the treatment compared to control patients who did not receive any treatment. Meanwhile, patients in the second and third trials typically did not need transfusions after just one week of the erythropoietin therapy. On average it took seven weeks for patients in the second trial and only four weeks for patients in the third trial to reach normal hemoglobin levels (12 g/dL).

While this study was small, the results suggest erythropoietin therapy is most successful after 35 days following transplant. The researchers believe this is when the bone marrow has recovered and is able to produce red blood cells. This study sets the stage for a larger, more comprehensive study of the use of erythropoietin therapy in bone marrow transplant patients.

January 2003 Update

Back to Top

©2000–2006 President & Fellows of Harvard College
Sign Up Now For
Our FREE E-mail Newsletter

In each weekly issue of HEALTHbeat:

  • Get trusted advice from the doctors at Harvard Medical School
  • Learn tips for living a healthy lifestyle
  • Stay up-to-date on the latest developments in health
  • Plus, receive your FREE Bonus Report, Living to 100: What's the secret?

[ Maybe Later ] [ No Thanks ]